Selecting appropriate first line lung cancer therapy
8 Jul 2009
Selecting appropriate first line lung cancer therapy
PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast cancer
Targeting death receptors in chemo-resistant cancer cells
AACR 2009: Tackling the p53 gene and side effects
AACR 2009: Chemokine inhibitors to prevent tumour growth
AACR 2009: Preclinical Analysis of Combined PI3K and MEK Inhibition as a Strategy for the Treatment of Cancer
Effects of Myelodysplastic Syndrome
Clinical research needs better interpretation
Professor José Baselga, ESMO and Professor Martine Piccart, BIG
Tailored Therapy - Increase Efficacy of Cetuximab